**5. Conclusions**

We have moved from one paradigm to another: instead of an exclusively ovarian origin, it appears that ovarian cancer may also have a tubal origin (probably in the majority of genetic risk cases) with the consequent questions concerning clinical implications and exclusively preventive salpingectomy.

We consider that more studies are still needed in order to validate these new concepts. It is clear now that, just as for breast cancer, ovarian cancer is a heterogeneous disease involving specific molecular signatures. Molecular characteristics may likely define personalized treatment specific to subtypes as is the case in breast cancer [31].
